A 18-month, Open-label, Rater-blinded, Randomized, Multi-center, Active-controlled, Parallel-group Pilot Study to Assess Efficacy and Safety of Fingolimod in Comparison to Interferon Beta 1b in Treating the Cognitive Symptoms Associated to Relapsing-remitting Multiple Sclerosis and to Assess Possible Relationship of These Effects to Regional Brain Atrophy

Aún no traducido Aún no traducido
Autores
Categoría Estudio primario
Registro de estudiosclinicaltrials.gov
Año 2011

Este artículo no está incluido en ninguna revisión sistemática

Este artículo es parte de los siguientes hilos de publicación
Cargando información sobre las referencias
The purpose of this pilot study is to evaluate, by means of a specific cognitive test battery (Brief Repeatable Battery and Delis-Kaplan Executive Function System scale), the slowing/reduction of cognitive dysfunction progression in RRMS patients after 18 months of treatment with fingolimod in comparison with interferon beta 1b treatment, and to evaluate which test of the battery is the most sensitive in detecting differences between treatment groups.
Epistemonikos ID: 5eeb51c93ebd7bfd3de139ea2fc8f2e5034240bd
First added on: Nov 02, 2021